Search Results - "Arguiñano, Jose M."

Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma by Rosiñol, Laura, Oriol, Albert, Rios, Rafael, Sureda, Anna, Blanchard, María Jesús, Hernández, Miguel Teodoro, Martínez-Martínez, Rafael, Moraleda, Jose M., Jarque, Isidro, Bargay, Juan, Gironella, Mercedes, de Arriba, Felipe, Palomera, Luis, González-Montes, Yolanda, Martí, Josep M., Krsnik, Isabel, Arguiñano, Jose M., González, Maria Esther, González, Ana Pilar, Casado, Luis Felipe, López-Anglada, Lucia, Paiva, Bruno, Mateos, Maria-Victoria, San Miguel, Jesus F., Lahuerta, Juan-José, Bladé, Joan

“…Achieving and maintaining a high-quality response is the treatment goal for patients with newly diagnosed multiple myeloma (NDMM). The phase 3 PETHEMA/GEM2012…”
Get full text

Safety of switching from intravenous to subcutaneous rituximab during first‐line treatment of patients with non‐Hodgkin lymphoma: the Spanish population of the MabRella study by García‐Muñoz, Ricardo, Quero, Cristina, Pérez‐Persona, Ernesto, Domingo‐García, Abel, Pérez‐López, Cristina, Villaescusa‐de‐la‐Rosa, Teresa, Martínez‐Castro, Ana M., Arguiñano‐Pérez, José M., Parra‐Cuadrado, Juan F., Panizo, Carlos

“…Summary Rituximab is a standard treatment for non‐Hodgkin diffuse large B‐cell (DLBCL) and follicular (FL) lymphomas. A subcutaneous formulation was developed…”
Get full text

Real-World Health Care Services Utilization Associated With the Management of Patients With Relapsed and Refractory Multiple Myeloma in Spain: The CharisMMa Study by Ocio, Enrique M., Montes-Gaisán, Carmen, Bustamante, Gabriela, Garzón, Sebastián, González, Esther, Pérez-Persona, Ernesto, González-Calle, Verónica, Sirvent, Maialen, Arguiñano, José M., González, Yolanda, Ríos, Rafael, de Miguel, Dunia, Grande, Marta, Fernández-Nistal, Alonso, Naves, Andrea, Rosiñol, Laura

“…Most patients with multiple myeloma (MM) relapse or become refractory, resulting in high health care costs. However, real-world data regarding the utilization…”
Get full text

Single-Agent Ibrutinib As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL) in Routine Clinical Practice in Spain by Abrisqueta Costa, Pau, Loscertales, Javier, Terol, Maria Jose, Ramirez Payer, Angel, Ortiz Pareja, Macarena, Perez, Inmaculada, Cuellar, Carolina, Fernandez De La Mata, Margarita, Rodriguez, Alicia, Lario, Ana, Delgado, Julio, Godoy, Ana Cristina, Arguiñano, Jose M, Berruezo, Maria José, Oliveira, Ana C, Hernandez-Rivas, Jose Angel, García-Malo, María-Dolores, Medina, Angeles, García Martín, Paloma, Osorio-Prendes, Santiago, Baltasar, Patricia, Fernandez, Miguel, Marco, Fernando, Vidal, María-Jesús, Smucler Simonovich, Alicia Susana, Lopez Rubio, Montserrat, Jarque, Isidro, Suárez Cabrera, Alexia, Fernandez, Ruben, Lancharro Anchel, Aima, Rios Herranz, Eduardo, Losada, Carmen, Pérez Persona, Ernesto, Garcia, Ricardo Francisco, Ramos, Rafael, Yáñez, Lucrecia, Bello, Jose Luis, Loriente, Cristina, Villanueva, Miguel

“…Introduction. Ibrutinib is a first-in-class, oral, once-a-day Bruton's tyrosine kinase inhibitor that achieves high overall response rates and durable…”
Get full text

Bortezomib, Lenalidomide and Dexamethasone (VRD-GEM) As Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): Results of a Prospective Phase III Pethema/GEM Trial by Rosinol, Laura, Oriol, Albert, Rios, Rafael, Sureda, Anna, Blanchard, M Jesús, Hernández, Miguel T, Martínez-Martínez, Rafael, Moraleda, Jose M, Jarque, Isidro, Bargay, Juan, Gironella, Mercedes, Moreno, Maria José, Palomera, Luis, Gonzalez-Montes, Yolanda, Marti, Josep M, Krsnik, Isabel, Arguiñano, Jose M, González, Maria Esther, González, Ana Pilar, Casado, Felipe, Lopez-Anglada, Lucía, Paiva, Bruno, Mateos, Maria-Victoria, San Miguel, Jesus F., Lahuerta, Juan-José, Blade, Joan

“…Introduction: In September 2013, the Spanish Myeloma Group (PETHEMA/GEM) activated a randomized phase III trial of induction therapy with VRD-GEM for 6 cycles…”
Get full text

P-090: Immune biomarkers of survival and infectionrelated mortality in multiple myeloma (MM) patients treated with lenalidomide and dexamethasone (Rd) by Maia, Catarina, Puig, Noemí, Cedena, Maria-Teresa, Gutiérrez, Norma, Calassanz, María-J, Martín-Ramos, Maria-L, Garcia, Miguel Teodoro Hernandez, Rosiñol, Laura, González, Mª Esther, de la Fuente, Felipe de Arriba, Oriol, Albert, González, Verónica, Escalante, Fernando, De la Rubia, Javier, Mesa, Mercedes Gironella, Ríos, Rafael, García-Sánchez, Ricarda, Arguiñano, José-M, Alegre, Adrián, San-Miguel, Jesus, Palacios, Juan José Lahuerta, Blade, Joan, Niesvizky, Ruben, Mateos, María-Victoria, Paiva, Bruno

Get full text

Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial by Puig, Noemi, Hernández, Miguel T., Rosiñol, Laura, González, Esther, de Arriba, Felipe, Oriol, Albert, González-Calle, Verónica, Escalante, Fernando, de la Rubia, Javier, Gironella, Mercedes, Ríos, Rafael, García-Sánchez, Ricarda, Arguiñano, José M., Alegre, Adrián, Martín, Jesús, Gutiérrez, Norma. C., Calasanz, María J., Martín, María L., Couto, María del Carmen, Casanova, María, Arnao, Mario, Pérez-Persona, Ernesto, Garzón, Sebastián, González, Marta S., Martín-Sánchez, Guillermo, Ocio, Enrique M., Coleman, Morton, Encinas, Cristina, Vale, Ana M., Teruel, Ana I., Cortés-Rodríguez, María, Paiva, Bruno, Cedena, M. Teresa, San-Miguel, Jesús F., Lahuerta, Juan J., Bladé, Joan, Niesvizky, Ruben, Mateos, María-Victoria

“…Although case-control analyses have suggested an additive value with the association of clarithromycin to continuous lenalidomide and dexamethasone (Rd), there…”
Get full text

Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma by Guerrero, Camila, Puig, Noemi, Cedena, María-Teresa, Calasanz, María-José, Gutierrez, Norma C., Fernandez, Manuela, Oriol, Albert, Ríos-Tamayo, Rafael, Hernandez, Miguel-Teodoro, Martínez-Martínez, Rafael, Bargay, Joan, de Arriba, Felipe, Palomera, Luis, Gonzalez-Rodriguez, Ana Pilar, Gonzalez Perez, Marta-Sonia, Orfao, Alberto, Mateos, María-Victoria, Martinez-Lopez, Joaquin, Rosiñol, Laura, Bladé, Joan, Lahuerta, Juan-Jose, San-Miguel, Jesus F., Paiva, Bruno, Casanova Espinosa, María, Zamudio, José Luís Guzman, Ríos Herranz, Eduardo, Rios Tamayo, Rafael, Martín Sánchez, Jesús, Palomera Bernal, Luís, González Rodríguez, Ana Pilar, González García, María Esther, Mayol, Antonia Sampol, Bargay Lleonart, Joan, Suárez, Alexia, Hernández García, Miguel Teodoro, Gaisán, Carmen Montes, Hernández Ruiz, Belén, Casado Montero, Felipe, Miguel Llorente, Dunia de, Ramos, Fernando Solano, Ibañez Garcia, Ángela, Manteca, Mariví Mateos, Mariano Hernández Martín, José, Escalante Barrigón, Fernando, García Frade, Javier, de Coca, Alfonso García, Franco, Carlos Aguilar, Labrador Gómez, Jorge, Cabezudo Pérez, Elena, Bladé Creixentí, Joan, Balari, Ana Ma Sureda, González Montes, Yolanda, Teigell, Lourdes Escoda, García Guiñón, Antonio, Abella Monreal, Eugenia, Alfonso Soler Campos, Juan, Martí Tutusaus, Josep Ma, Rocafiguera, Albert Oriol, Gorrochategui, Miquel Granell, Mesa, Mercedes Gironella, Silva, Carmen Cabrera, González Pérez, Marta Sonia, Loureiro, Ana Dios, Méndez Sánchez, José Angel, Irazu, María Josefa Nájera, Párraga, Francisco Javier Peñalver, Lahuerta Palacios, Juan José, Barahona, Pilar Bravo, Rodríguez, Cristina Encinas, Hernández Rivas, José Ángel, Oteyza, Jaime Pérez de, Iglesias del Barrio, Rebeca, López de la Guia, Ana, Amor, Adrián Alegre, Prieto Pareja, Elena, Castelló, Isabel Krsnik, Blanchard Rodríguez, Ma Jesús, Martínez Martínez, Rafael, Riaza Grau, Rosalía, Mesa, Eugenio Giménez, Ruiz Sainz, Elena, Arriba, Felipe de, Moraleda Jiménez, Jose María, Romera, Marta, Cardoso, Felipe Prósper, Arguiñano Pérez, José Ma, Pomposo, María Puente, Pérez Persona, Ernesto, Teruel Casasús, Ana Isabel, García, Paz Ribas, Jarque Ramos, Isidro, Villarrubia Lor, María Blanca, Fernández García, Pedro Luis, Martínez Chamorro, Carmen

“…•ISS 3, high CTC levels, and a longer time to first MRD negativity are significant predictors of MRD resurgence and/or progressive disease. [Display omitted]…”
Get full text

Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial by Mateos, María-Victoria, Dr, Hernández, Miguel-Teodoro, MD, Giraldo, Pilar, MD, de la Rubia, Javier, MD, de Arriba, Felipe, PhD, Corral, Lucía López, PhD, Rosiñol, Laura, PhD, Paiva, Bruno, PhD, Palomera, Luis, PhD, Bargay, Joan, PhD, Oriol, Albert, MD, Prosper, Felipe, PhD, López, Javier, PhD, Arguiñano, José-María, MD, Quintana, Nuria, MD, García, José-Luis, MD, Bladé, Joan, PhD, Lahuerta, Juan-José, PhD, Miguel, Jesús-F San, Prof

“…Summary Background The standard of care for smouldering multiple myeloma is observation. We did the QuiRedex study to compare early treatment with lenalidomide…”
Get full text